JP2023554524A5 - - Google Patents
Info
- Publication number
- JP2023554524A5 JP2023554524A5 JP2023537995A JP2023537995A JP2023554524A5 JP 2023554524 A5 JP2023554524 A5 JP 2023554524A5 JP 2023537995 A JP2023537995 A JP 2023537995A JP 2023537995 A JP2023537995 A JP 2023537995A JP 2023554524 A5 JP2023554524 A5 JP 2023554524A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- combination therapy
- use according
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128996P | 2020-12-22 | 2020-12-22 | |
| US63/128,996 | 2020-12-22 | ||
| PCT/IB2021/062115 WO2022137125A1 (en) | 2020-12-22 | 2021-12-21 | Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023554524A JP2023554524A (ja) | 2023-12-27 |
| JP2023554524A5 true JP2023554524A5 (cg-RX-API-DMAC7.html) | 2024-12-26 |
Family
ID=79283090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537995A Pending JP2023554524A (ja) | 2020-12-22 | 2021-12-21 | 非アルコール性脂肪性肝炎の治療のための酸素含有構造強化脂肪酸を含む組合せ療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240325336A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4267124A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023554524A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230128307A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116829139A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021405273A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3201254A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023007347A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022137125A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009061208A1 (en) | 2007-11-09 | 2009-05-14 | Pronova Biopharma Norge As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
| KR101783817B1 (ko) | 2009-05-08 | 2017-10-23 | 프로노바 바이오파마 너지 에이에스 | 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산 |
| TW201138832A (en) | 2010-01-20 | 2011-11-16 | Pronova Biopharma Norge As | Salicylate fatty acid derivatives |
| SG10201509127YA (en) * | 2010-11-05 | 2015-12-30 | Pronova Biopharma Norge As | Methods of treatment using lipid compounds |
| WO2014132135A2 (en) | 2013-02-28 | 2014-09-04 | Pronova Biopharma Norge As | Methods of preparing fatty acid derivatives |
| US11351139B2 (en) * | 2013-02-28 | 2022-06-07 | Basf As | Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
| WO2016156912A1 (en) | 2015-04-01 | 2016-10-06 | Pronova Biopharma Norge As | Use of thia oxo compounds for lowering apo c3 |
| AU2016256552B2 (en) | 2015-04-28 | 2021-04-01 | Pronova Biopharma Norge As | Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis |
| EP3350165B1 (en) * | 2015-09-16 | 2023-07-26 | Organovo, Inc. | Farnesoid x receptor agonists and uses thereof |
| US20190142905A1 (en) * | 2016-04-19 | 2019-05-16 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
| MX2019007789A (es) * | 2016-12-28 | 2019-10-21 | Modunex Bio Corp | Terapia de combinacion para esteatohepatitis no alcoholica (nash) y fibrosis hepatica. |
| CA3058542A1 (en) * | 2017-04-18 | 2018-10-25 | Genfit | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor |
| IL308604B2 (en) * | 2017-12-06 | 2025-08-01 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| US20220047553A1 (en) * | 2018-09-18 | 2022-02-17 | Metacrine, Inc. | Farnesoid x receptor agonists for the treatment of disease |
-
2021
- 2021-12-21 JP JP2023537995A patent/JP2023554524A/ja active Pending
- 2021-12-21 US US18/258,620 patent/US20240325336A1/en active Pending
- 2021-12-21 AU AU2021405273A patent/AU2021405273A1/en active Pending
- 2021-12-21 EP EP21839683.6A patent/EP4267124A1/en active Pending
- 2021-12-21 CA CA3201254A patent/CA3201254A1/en active Pending
- 2021-12-21 KR KR1020237024993A patent/KR20230128307A/ko active Pending
- 2021-12-21 WO PCT/IB2021/062115 patent/WO2022137125A1/en not_active Ceased
- 2021-12-21 CN CN202180086806.5A patent/CN116829139A/zh active Pending
- 2021-12-21 MX MX2023007347A patent/MX2023007347A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI852999B (zh) | 治療脂肪性肝病及/或脂肪性肝炎的方法 | |
| JP2021505591A5 (cg-RX-API-DMAC7.html) | ||
| US12440466B2 (en) | Fatty acid derivatives for treating non-alcoholic steatohepatitis | |
| CN100352433C (zh) | 用于治疗炎症的脂肪醇和脂肪酸酯 | |
| RU2019137026A (ru) | Сложные эфиры для лечения офтальмологических воспалительных заболеваний | |
| MX366137B (es) | Acidos grasos poliinsaturados para el tratamiento de trastornos relacionados a las areas de los trastornos cardiovasculares, metabolicos e inflamatorios. | |
| JP2018515463A5 (cg-RX-API-DMAC7.html) | ||
| JP2024095711A (ja) | 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール | |
| RU2019113150A (ru) | Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения | |
| KR101466617B1 (ko) | 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제 | |
| RU2017137960A (ru) | Применение тиаоксосоединений для уменьшения содержания аро сз | |
| CL2021000846A1 (es) | Compuestos aromáticos y usos farmacéuticos de los mismos | |
| JP6650006B2 (ja) | 脂質異常症治療剤 | |
| JP2023554524A (ja) | 非アルコール性脂肪性肝炎の治療のための酸素含有構造強化脂肪酸を含む組合せ療法 | |
| TW202423441A (zh) | 治療塵肺病的方法 | |
| HK40054971B (en) | Method for treating fatty liver disease and/or steatohepatitis | |
| JP2020090448A (ja) | アレルギー性結膜炎予防又は治療剤 |